(Q38149195)

29 August 2017

Therapeutic antibodies as a treatment option for dengue fever (English)

1 reference

29 August 2017

0 references

Eugenia Z Ong

2

0 references

Eng Eong Ooi

object named as

Eng Eong Ooi

series ordinal

3

0 references

author name string

Kuan Rong Chan

series ordinal

1

1 reference

29 August 2017

4 October 2013

1 reference

Expert Review of Anti-infective Therapy

29 August 2017

1 reference

29 August 2017

11

1 reference

29 August 2017

11

1 reference

29 August 2017

1147-1157

1 reference

The global distribution and burden of dengue

29 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

The changing epidemiology of yellow fever and dengue, 1900 to 2003: full circle?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Dengue and dengue haemorrhagic fever

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Antibody to dengue 1 detected more than 60 years after infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Immune response to dengue virus and prospects for a vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Maternal antibody and viral factors in the pathogenesis of dengue virus in infants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Pathogenesis of dengue: challenges to molecular biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Dengue prevention and 35 years of vector control in Singapore

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Antibody-enhanced dengue virus infection in primate leukocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Immunogenicity of sanofi pasteur tetravalent dengue vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Dengue viral RNA levels in peripheral blood mononuclear cells are associated with disease severity and preexisting dengue immune status

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Potent antibody therapeutics by design

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Improving the efficacy of antibody-based cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Engineering antibodies for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

The growth and potential of human antiviral monoclonal antibody therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Passive immunity in prevention and treatment of infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Antibodies to Envelope Glycoprotein of Dengue Virus during the Natural Course of Infection Are Predominantly Cross-Reactive and Recognize Epitopes Containing Highly Conserved Residues at the Fusion Loop of Domain II

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Cross-reacting antibodies enhance dengue virus infection in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

SDR grafting--a new approach to antibody humanization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Identification and characterization of a human monoclonal antibody that potently neutralizes a broad panel of rabies virus isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Selecting and screening recombinant antibody libraries

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Human monoclonal antibodies by immortalization of memory B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Palivizumab prophylaxis of respiratory syncytial virus disease in 2000–2001: Results from the palivizumab outcomes registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Structure of dengue virus: implications for flavivirus organization, maturation, and fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Dengue virus envelope glycoprotein structure: New insight into its interactions during viral entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Genotype-specific neutralization and protection by antibodies against dengue virus type 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Monoclonal Antibodies That Bind to Domain III of Dengue Virus E Glycoprotein Are the Most Efficient Blockers of Virus Adsorption to Vero Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

The Development of Therapeutic Antibodies That Neutralize Homologous and Heterologous Genotypes of Dengue Virus Type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Recombinant dengue type 2 viruses with altered e protein domain III epitopes are efficiently neutralized by human immune sera

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

The structural basis for serotype-specific neutralization of dengue virus by a human antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Human Monoclonal Antibodies against West Nile Virus Induced by Natural Infection Neutralize at a Postattachment Step

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Natural Strain Variation and Antibody Neutralization of Dengue Serotype 3 Viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Resistance analysis of an antibody that selectively inhibits dengue virus serotype-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Protection by immunoglobulin dual-affinity retargeting antibodies against dengue virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

A multi-hit model for the neutralization of animal viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Antibody-mediated neutralization of flaviviruses: a reductionist view

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

The Stoichiometry of Antibody-Mediated Neutralization and Enhancement of West Nile Virus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Structural Insights into the Mechanisms of Antibody-Mediated Neutralization of Flavivirus Infection: Implications for Vaccine Development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

A new mechanism for the neutralization of enveloped viruses by antiviral antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Heat shock protein 90 and heat shock protein 70 are components of dengue virus receptor complex in human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

CLEC5A is critical for dengue-virus-induced lethal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

The mannose receptor mediates dengue virus infection of macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Ligation of Fc gamma receptor IIB inhibits antibody-dependent enhancement of dengue virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Dissecting the cell entry pathway of dengue virus by single-particle tracking in living cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

The phagosome: compartment with a license to kill

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

A Therapeutic Antibody against West Nile Virus Neutralizes Infection by Blocking Fusion within Endosomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Complement-dependent virolysis of HIV-1 with monoclonal antibody NM-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Infection-Enhancing and -Neutralizing Activities of Mouse Monoclonal Antibodies against Dengue Type 2 and 4 Viruses Are Controlled by Complement Levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Complement Protein C1q Inhibits Antibody-Dependent Enhancement of Flavivirus Infection in an IgG Subclass-Specific Manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Monocytes, but not T or B cells, are the principal target cells for dengue virus (DV) infection among human peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Neutralization of dengue virus in the presence of Fc receptor-mediated phagocytosis distinguishes serotype-specific from cross-neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Redesign of a cross-reactive antibody to dengue virus with broad-spectrum activity and increased in vivo potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Therapeutic efficacy of antibodies lacking Fcγ receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Facing the enigma of immunomodulatory effects of intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Characteristics of dengue virus-infected peripheral blood mononuclear cell death that correlates with the severity of illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Enhanced Infection of Liver Sinusoidal Endothelial Cells in a Mouse Model of Antibody-Induced Severe Dengue Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Crystal structure of the complex of rat neonatal Fc receptor with Fc

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

An engineered human IgG1 antibody with longer serum half-life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Engineering therapeutic monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Neutralizing and non-neutralizing monoclonal antibodies against dengue virus E protein derived from a naturally infected patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Persistence of circulating memory B cell clones with potential for dengue virus disease enhancement for decades following infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Human monoclonal antibodies to neutralize all dengue virus serotypes using lymphocytes from patients at acute phase of the secondary infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Dengue seroepidemiology in Singapore

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.839941

Research on dengue during World War II

21 January 2018

1 reference

21 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.4269/AJTMH.1952.1.30

Identifiers

DOI

10.1586/14787210.2013.839941

1 reference

29 August 2017

1 reference

PubMed ID

24093625